Free Trial

Biodesix (BDSX) Competitors

Biodesix logo
$0.31 -0.01 (-3.39%)
Closing price 04:00 PM Eastern
Extended Trading
$0.31 +0.00 (+0.52%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BDSX vs. XGN, EUDA, SERA, QIPT, NAKA, KDLY, ATPC, CORBF, OPGN, and PIII

Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Exagen (XGN), EUDA Health (EUDA), Sera Prognostics (SERA), Quipt Home Medical (QIPT), KindlyMD (NAKA), Kindly MD (KDLY), Agape ATP (ATPC), Global Cord Blood (CORBF), OpGen (OPGN), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.

Biodesix vs. Its Competitors

Exagen (NASDAQ:XGN) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

75.3% of Exagen shares are held by institutional investors. Comparatively, 21.0% of Biodesix shares are held by institutional investors. 12.6% of Exagen shares are held by insiders. Comparatively, 30.1% of Biodesix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Exagen has a beta of 1.58, suggesting that its stock price is 58% more volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.

In the previous week, Exagen and Exagen both had 1 articles in the media. Exagen's average media sentiment score of 0.00 equaled Biodesix'saverage media sentiment score.

Company Overall Sentiment
Exagen Neutral
Biodesix Neutral

Exagen presently has a consensus target price of $7.50, suggesting a potential upside of 7.14%. Biodesix has a consensus target price of $1.75, suggesting a potential upside of 473.02%. Given Biodesix's higher possible upside, analysts clearly believe Biodesix is more favorable than Exagen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exagen
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Biodesix
0 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.80

Exagen has higher earnings, but lower revenue than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exagen$55.64M2.68-$15.11M-$0.84-8.33
Biodesix$71.32M0.63-$42.93M-$0.29-1.05

Exagen has a net margin of -27.34% compared to Biodesix's net margin of -54.28%. Exagen's return on equity of -133.69% beat Biodesix's return on equity.

Company Net Margins Return on Equity Return on Assets
Exagen-27.34% -133.69% -34.87%
Biodesix -54.28%-167.28%-39.96%

Summary

Exagen beats Biodesix on 9 of the 14 factors compared between the two stocks.

Get Biodesix News Delivered to You Automatically

Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BDSX vs. The Competition

MetricBiodesixMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$46.33M$7.28B$5.56B$9.04B
Dividend YieldN/A2.81%5.25%4.03%
P/E Ratio-1.0518.9819.5820.23
Price / Sales0.6329.96442.27127.79
Price / CashN/A24.4037.5058.41
Price / Book2.186.888.085.60
Net Income-$42.93M$230.16M$3.16B$248.43M
7 Day Performance10.65%2.22%3.77%5.15%
1 Month Performance-7.45%2.64%3.90%7.62%
1 Year Performance-81.15%45.06%34.22%21.56%

Biodesix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BDSX
Biodesix
3.3956 of 5 stars
$0.31
-3.4%
$1.75
+473.0%
-80.5%$46.33M$71.32M-1.05220Positive News
XGN
Exagen
2.9715 of 5 stars
$6.96
-1.3%
$7.50
+7.8%
+261.4%$150.16M$55.64M0.00220
EUDA
EUDA Health
0.4696 of 5 stars
$3.33
-1.5%
N/A-15.9%$125.59M$4.01M0.002Gap Down
SERA
Sera Prognostics
0.6519 of 5 stars
$2.42
-2.8%
N/A-49.7%$93.81M$80K0.00120News Coverage
QIPT
Quipt Home Medical
2.9619 of 5 stars
$1.73
-2.8%
$2.85
+64.7%
-36.3%$77.33M$245.91M0.001,200Analyst Revision
NAKA
KindlyMD
N/A$12.04
-5.6%
N/AN/A$76.88M$2.72M-15.64N/ANews Coverage
KDLY
Kindly MD
N/A$12.75
-2.8%
N/A+426.9%$76.78M$2.47M-16.56N/A
ATPC
Agape ATP
0.2334 of 5 stars
$1.40
+2.6%
N/A-64.4%$68.01M$1.32M-2.3240News Coverage
CORBF
Global Cord Blood
N/A$0.55
-62.1%
N/A-54.1%$66.85M$196.12M0.001,200Gap Up
OPGN
OpGen
N/A$5.02
+6.1%
N/A+59.2%$50.54M$2.67M0.00100Gap Down
PIII
P3 Health Partners
2.9195 of 5 stars
$6.40
+0.3%
$16.25
+153.9%
-74.4%$45.86M$1.50B0.00500

Related Companies and Tools


This page (NASDAQ:BDSX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners